Center for Clinical Studies

Running trials

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· Phase 3· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Source

• Recruiting

  A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

  NCT06857942· Phase 4· Source

• Recruiting

  Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

  NCT06397911· Phase 2· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

  NCT06220604· Phase 3· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  NCT06143878· Phase 3· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

  NCT06095102· Phase 3· Source

• Active, not recruiting

  A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

  NCT06095115· Phase 3· Source

• Active, not recruiting

  A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

  NCT03661866· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Psoriasis2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Obesity1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

  NCT05571943· Phase 3· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Source